We are live on
!
Find out more
PM
Penbrook Management Portfolio holdings
AUM
$157M
1-Year Est. Return
46.57%
This Fund
S&P 500
This Quarter
Est. Return
-14.31%
1 Year Est. Return
+46.57%
3 Year Est. Return
+102.93%
5 Year Est. Return
+150.44%
10 Year Est. Return
–
AUM
$127M
AUM Growth
-$27.3M
(-18%)
Cap. Flow
-$1.6M
Cap. Flow
% of AUM
-1.26%
Top 10 Holdings %
Top 10 Hldgs %
43.52%
Holding
112
New
3
Increased
9
Reduced
48
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
EGIO
Edgio, Inc. Common Stock
EGIO
|
+$647K |
| 2 |
Airbnb
ABNB
|
+$455K |
| 3 |
Dorchester Minerals
DMLP
|
+$384K |
| 4 |
IBM
IBM
|
+$361K |
| 5 |
Vermilion Energy
VET
|
+$283K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$540K |
| 2 |
CYBE
Cyberoptics Corp
CYBE
|
+$427K |
| 3 |
OptimizeRx
OPRX
|
+$399K |
| 4 |
Intellicheck
IDN
|
+$371K |
| 5 |
TWOU
2U Inc
TWOU
|
+$367K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 22.7% |
| 2 | Technology | 22.57% |
| 3 | Energy | 12.98% |
| 4 | Financials | 10.58% |
| 5 | Industrials | 8.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Regeneron Pharmaceuticals
REGN
$78.2B
| $752K | 0.59% |
1,272
| – | – |
|
52
Invesco S&P 500 Equal Weight Energy ETF
RSPG
$559M
| $724K | 0.57% |
11,765
-100
| -0.8% | -$7K |
|
53
BioLife Solutions
BLFS
$1.57B
| $667K | 0.53% |
48,315
-300
| -0.6% | -$4.4K |
|
|
ATCX
54
DELISTED
Atlas Technical Consultants, Inc. Class A Common Stock
ATCX
| $640K | 0.5% |
121,745
-650
| -0.5% | -$6.15K |
|
|
PIM
55
Franklin Master Intermediate Income Trust
PIM
$150M
| $638K | 0.5% |
187,052
-5,850
| -3% | -$20.3K |
|
56
Shell
SHEL
$252B
| $633K | 0.5% |
12,100
-110
| -0.9% | -$6.18K |
|
|
57
IBM
IBM
$213B
| $619K | 0.49% |
4,385
+2,675
| +156% | +$361K |
|
|
BKI
58
DELISTED
Black Knight, Inc. Common Stock
BKI
| $609K | 0.48% |
9,318
| – | – |
|
59
CNX Resources
CNX
$5.33B
| $593K | 0.47% |
36,000
-200
| -0.6% | -$4.1K |
|
|
MESO
60
Mesoblast
MESO
$1.88B
| $568K | 0.45% |
127,825
-100
| -0.1% | -$688 |
|
61
First American
FAF
$7.7B
| $548K | 0.43% |
10,350
| – | – |
|
62
Cenovus Energy
CVE
$54.5B
| $547K | 0.43% |
28,800
| – | – |
|
63
Novartis
NVS
$292B
| $546K | 0.43% |
6,460
| – | – |
|
64
Immersion
IMMR
$248M
| $531K | 0.42% |
99,420
-37,600
| -27% | -$195K |
|
|
IMDX
65
Insight Molecular Diagnostics
IMDX
$162M
| $518K | 0.41% |
28,788
-120
| -0.4% | -$2.73K |
|
66
Exagen
XGN
$113M
| $506K | 0.4% |
88,100
-500
| -0.6% | -$2.91K |
|
67
iShares Biotechnology ETF
IBB
$9.18B
| $483K | 0.38% |
4,110
-60
| -1% | -$7.12K |
|
68
Becton Dickinson
BDX
$46.9B
| $473K | 0.37% |
1,920
-58
| -3% | -$14.7K |
|
69
Invesco S&P 500 Equal Weight ETF
RSP
$98.1B
| $464K | 0.37% |
3,460
| – | – |
|
70
Emerson Electric
EMR
$86.7B
| $461K | 0.36% |
5,800
| – | – |
|
71
Chegg
CHGG
$114M
| $432K | 0.34% |
23,015
-100
| -0.4% | -$2.29K |
|
|
EGIO
72
DELISTED
Edgio, Inc. Common Stock
EGIO
| $415K | 0.33% |
+4,494
| New | +$647K |
|
|
FISV
73
Fiserv Inc
FISV
$29B
| $408K | 0.32% |
4,591
| – | – |
|
74
Barrett Business Services
BBSI
$979M
| $401K | 0.32% |
22,000
-800
| -4% | -$14.7K |
|
75
Lincoln Educational Services
LINC
$1.37B
| $393K | 0.31% |
62,305
-500
| -0.8% | -$3.14K |
|
Similar funds
IWM
EP
AC
SF
LAM
HAM
HEM
CF
Penbrook Management's Q2 2022 Portfolio in Review
As of Q2 2022, Penbrook Management held 112 positions worth $127M, down 18% from $154M the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Penbrook Management's Q2 2022 filing shows 3 new, 9 increased, 48 reduced and 6 closed positions. Its largest new stake was Edgio, Inc. Common Stock: 4,494 shares worth $415K. The largest sale was Microsoft, an estimated $540K.
By sector, the portfolio is most concentrated in Healthcare at 23% of assets, up from 21% a quarter earlier, followed by Technology and Energy.
- Penbrook Management's largest Q2 2022 buy was Edgio, Inc. Common Stock: 4,494 shares worth $415K.
- Penbrook Management added most to IBM in Q2 2022, an estimated $361K increase.
- Penbrook Management's biggest Q2 2022 reduction was Microsoft, cutting an estimated $540K.
- Penbrook Management fully exited OptimizeRx in Q2 2022, selling an estimated $399K.
- Penbrook Management's ten largest holdings make up 44% of its $127M portfolio in Q2 2022.
- Penbrook Management opened 3 new positions and closed 6 in Q2 2022.
- Penbrook Management's portfolio value fell 18% quarter-over-quarter to $127M.
Based on Penbrook Management's 13F filing for Q2 2022, filed 29 Jul 2022.